



ENDOCTE

Jonathan M. Shillingford, Ph.D.
Associate Director, Cell Biology
Endocyte, Inc.
3000 Kent Ave
Suite A1-100
West Lafayette IN 47906
Direct: 765-807-0640
jshillingford@endocyte.com

United States Nuclear Regulatory Commission
Region III
2443 Warrenville Rd, Suite 210
Lisle, IL 60532-4352
ATTN: MATERIALS LICENSING
Re: Response for further information

Thursday January 19th, 2017

To Whom It May Concern,

In regard to our recent amendment request, please find clarification of the physical form of each of the radionuclides we recently requested to add to our current NRC license 13-32212-01;

1. Astatine-211; liquid ; in the form of astatide as a sodium salt solution
2. Radium-223; liquid ; in the form of a dichloride injection
3. Actinium-225; solid ; in the form of a dried nitrate solid
4. Yttrium-90; liquid ; in the form of yttrium chloride in 0.05 M HCl solution
5. Lutetium-177; liquid ; in the form of lutetium chloride in 0.05 M HCl solution

We appreciate your time in reviewing our request and, should you have any further questions or a need for additional clarification or information, please do not hesitate to contact me.

Sincerely yours,

Jonathan M. Shillingford, Ph.D.
Radiation Safety Officer

RECEIVED JAN 19 2017

3000 Kent Ave West Lafayette, IN 47906-1325 Tel: (765) 463-7175 Fax: (765) 463-9271



ENDOCTE

FAX COVERSHEET

To: Nuclear Regulatory Commission ; mail control # 592564

Fax: 630-515-1078

From: Jonathan Shillingford, RSO

Pages: 2 (including cover sheet)

Please find additional clarification for NRC license
13-32212-01 amendment enclosed.

with kind regards

3000 Kent Ave West Lafayette, IN 47906-1325 Tel: (765) 463-7175 Fax: (765) 463-9271